0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-180.90%PremiumJul 19, 2024Expiry Date0.64Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Brainstorm Cell Therapeutics Stock Discussion
BCLI Update - Progress Supports Our 10x Plus Value Range PotentialBCLIShare
ACF Equity Research
FROM ACF EQUITY RESEARCH HEALTHCARE TEAM
LONDON, July 24, 2024 /PRNewswire/ --
NASDAQ: BCLI
READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE
UPDATE NOTE: BrainStorm Cell Therapeutics...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b clinical trial for NurOwn, a therapy for amyotrophic lateral sclerosis (ALS). This development follows the FDA’s Special Protocol Assessment (SPA) agreement granted in April 2024, which provided ...
⚫️BCLI's primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig's).
▪️Post hoc analysis of BCLI's PIII trial data shows BCLI's NurOwn® (debamestrocel, MSC-NTF), has STATISTICALLY SIGNIFICANT clinical effects on early-stage ALS sufferers and that placebo trialists deteriorate faster.
▪️Peer reviewed research (Mar 2024) indicated that BCLI's NurOwn® has a positive impact on NfL biomarkers...
No comment yet